Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished

Comment

P Bentham et al. BMJ. 1999.

. 1999 Sep 4;319(7210):640-1.

doi: 10.1136/bmj.319.7210.640a.

No abstract available

Comment in

Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
Bullock R, Passmore P, Wilkinson D, Howard R, Jones R. Bullock R, et al. BMJ. 2000 Feb 19;320(7233):511-2. BMJ. 2000. PMID: 10678874 Free PMC article. No abstract available.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M. Rösler M, et al. BMJ. 1999 Mar 6;318(7184):633-8. doi: 10.1136/bmj.318.7184.633. BMJ. 1999. PMID: 10066203 Free PMC article. Clinical Trial.

1. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. on behalf of the B303 Exelon study group. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial [commentary by Bayer T] BMJ 1999318633–639.. (6 March.) - PMC - PubMed
1. Corey-Bloom J, Anand R, Veach J.for the ENA 713 B352 Study. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease Int J Ger Psychopharmacol 1998155–65.
1. DeJong R, Osterlund OW, Roy GE. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther. 1989;11:545–554. - PubMed
1. Stein K. Rivastigmine (ExelonTM) in the treatment of senile dementia of the Alzheimer type (SDAT). Bristol:NHS Executive South and West; 1998. (Development and evaluation committee report No 89.)
1. DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther. 1989;11:545–554. - PubMed